Dynamics of renal function in patients with atrial fibrillation: interrelations with systemic fibrosis and arterial stiffness

The aim was to study the dynamics of renal function in relation to the fibrosis activity and the arterial stiffness in young and middle-aged patients with atrial fibrillation (AF). Materials and methods. 50 young and middle-aged men with AF were examined. The average age was 53.0 (48.0-58.0). The serum levels of creatinine and cystatin C (Cys C) were determined and the glomerular filtration rate (eGFR) was calculated initially and after 12 months. The activity of systemic fibrosis was assessed by serum metalloproteinase-2 (MMP-2) and transforming growth factor-ß1 (TGF-ß1) determining. To assess systemic vascular stiffness central aortic pressure and pulse wave velocity (PWV) were measured. Results. Renal impairment defined as eGFR decrease by more than 10 ml/min/1.73 m² or to the level below than 60 ml/min/1.73 m² throughout the year was registered in 10 (20.0 %) patients. The concentration of MMP-2 and TGF-ß1 was higher in the subgroup with the eGFR decline compared to the patients without renal function impairment (21.1 (17.4-25.9) and 16.5 (13.0-19.2) ng/ml (p = 0.038); 3.01 (0.09-17.4), and 0.08 (0-1.3) ng/ml (p = 0.041). Central aortic pulse pressure was also higher in the patients with eGFR decline (45.5 (42.0-49.0) and 38.0 (31.0-41.0) mmHg; p = 0.036). The PWV levels did not differ in the subgroups. Conclusion. The renal function impairment throughout a follow-up period of 12 months was registered in 20.0 % of young and middle-aged patients with AF. This subgroup of AF patients was characterized by increased activity of systemic fibrosis and vascular stiffness in terms of matrix metalloproteinase-2, transforming growth factor-ß1 and central aortic pulse pressure levels.

atrial fibrillation, chronic kidney disease, glomerular filtration rate, matrix metalloproteinase-2, transforming growth factor- beta 1, central pulse pressure

1. Драпкина О.М., Емельянов А.В. Фиброз и фибрилляция предсердий - механизмы и лечение // Артериальная гипертензия. - 2013. - № 6. - С. 487-494

2. Оскола Е.В., Шубина А.Т., Заирова А.Р., Андреевская М.В., Богиева Р.М., Погорелова О.А., Болотина М.Г., Балахонова Т.В., Рогоза А.Н., Карпов Ю.А. Эластические свойства сосудов, показатели функционального состояния почек и почечного кровотока у больных с ишемической болезнью сердца, гипертонической болезнью и сопутствующим сахарным диабетом 2 типа // Сахарный диабет. - 2014. - № 3. - С. 96-106. doi: 10.14341/DM2014396-106

3. Avci E., Avci G.A., Ozcelik B., Cevher S.C., Suicmez M. (2017). Transforming growth factor beta-1: an important biomarker for developing cardiovascular diseases in chronic renal failure. Bratisl Lek List, 118 (3), 175-178. doi: 10.4149/BLL_2017_035

4. Böhm M., Ezekowitz M.D., Connolly S.J., Eikelboom J.W., Hohnloser S.H., Reilly P.A., Schumacher H., Brueckmann M., Schirmer S.H., Kratz M.T., Yusuf S., Diener H.C., Hijazi Z., Wallentin L. (2015). Changes in renal function in patients with atrial fibrillation an analysis from the RE-LY trial. J Am Coll Cardiol, 65 (23), 2481-2493. doi: 10.1016/j.jacc.2015.03.577

5. Bukowska A., Lendeckel U., Krohn A., Keilhoff G., Ten Have S., Neumann K.H., Goette A. (2008). Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace, 10, 1212-1217. doi: 10.1093/europace/eun206.

6. Camm A.J., Kirchhof P., Lip G.Y.H., Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek B., Heldal M., Hohloser S.H., Kolh P., Le Heuzey J.Y., Ponikowski P., Rutten F.H.; ESC Committee for Practice Guidelines. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 12 (10), 1360-1420. doi: 10.1093/europace/euq350.

7. Chen S.C., Lee W.H., Hsu P.C., Lee C.S., Lee M.K., Yen H.W., Lin T.H., Voon W.C., Lai W.T., Sheu S.H., Su H.M. (2016). Association of the ratio of early mitral inflow velocity to the global diastolic strain rate with a rapid renal function decline in atrial fibrillation. PLoS One, 11 (1), e0147446. doi: 10.1371/journal.pone.0147446.

8. Climie R.E.D., Picone D.S., Sharman J.E. (2017). Longitudinal changes in excess pressure independently predict declining renal function among healthy individuals - a pilot study. Am J Hypertens, 30 (8), 772-775. doi: 10.1093/ajh/hpx091.

9. Cui R., Yamagishi K., Muraki I., Hayama-Terada M., Umesawa M., Imano H., Li Y., Eshak E.S., Ohira T., Kiyama M., Okada T., Kitamura A., Tanigawa T., Iso H., CIRCS investigators (2017). Association between markers of arterial stiffness and atrial fibrillation in the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 263, 244-248. doi: 10.1016/j.atherosclerosis.2017.06.918.

10. Genovesi S., Pogliani D., Faini A., Valsecchi M.G., Riva A., Stefani F., Acquistapace I., Stella A., Bonforte G., De-Vecchi A., DeCristofaro V., Buccianti G., Vincenti A. (2005). Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis, 46, 897-902. doi: 10.1053/j.ajkd.2005.07.044.

11. Hermanz M.M., Henry R., Dekker J.M., Kooman J.P., Kostense P.J., Nijpels G., Heine R.J., Stehouwer C.D. (2007). Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol, 18 (6), 1942-1952. doi:10.1681/ASN.2006111217.

12. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H.C., Heidbuchel H., Hendriks J., Hindricks G., Manolis A.S., Oldgren J., Popescu B.A., Schotten U., Van Putte B., Vardas P., Agewall S., Camm J., Baron Esquivias G., Budts W., Carerj S., Casselman F., Coca A., De Caterina R., Deftereos S., Dobrev D., Ferro J.M., Filippatos G., Fitzsimons D., Gorenek B., Guenoun M., Hohnloser S.H., Kolh P., Lip G.Y., Manolis A., McMurray J., Ponikowski P., Rosenhek R., Ruschitzka F., Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano J.L., Zeppenfeld K. (2016). 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37 (38), 2893-2962.

13. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L, Ducimetiere P., Benetos A. (2001). Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension, 37 (5), 1236-1241.

14. Mansour S.G., Puthumana J., Coca S.G., Gentry M., Parikh C.R. (2017). Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review. BMC Nephrol, 18 (1), 72. doi: 10.1186/s12882-017-0490-0.

15. Pastori D., Pignatelli P., Perticone F., Sciacqua A., Carnevale R., Farcomeni A., Basili S., Corazza G.R., Davî G., Lip G.Y., Violi F.; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) study group). (2016). Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. Int J Cardiol, 223, 619-624. doi: 10.1016/j.ijcard.2016.08.224.

16. Prineas R.J., Soliman E.Z., Howard G., Howard V.J., Cushman M., Zhang Z.M., Moy C.S. (2009). The sensitivity of the method used to detect atrial fibrillation in population studies affects group-specific prevalence estimates: ethnic and regional distribution of atrial fibrillation in the REGARDS study. J Epidemiol, 19 (4), 177-181. doi: 10.2188/jea.je20081032.

17. Roldan V., Marin F., Fernandez H., Manzano-Fernandez S., Gallego P., Valdés M., Vicente V., Lip G.Y. (2013). Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol, 111 (8), 1159-1164. doi: 10.1016/j.amjcard.2012.12.045.

18. Sangaralingham S.J., Wang B.H., Huang L., Kumfu S., Ichiki T., Krum H., Burnett J.C. Jr. (2016). Cardiorenal fibrosis and dysfunction in aging: imbalance in mediators and regulates of collagen. Peptides, 76, 108-114. doi: 10.1016/j.peptides.2016.01.004.

19. Yanagisawa S., Inden Y., Kato H., Fujii A., Mizutani Y., Ito T. (2017). Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation: A potential effect of non-pulmonary vein foci. J Cardiol, 69 (1), 3-10. doi: 10.1016/j. jjcc.2016.07.008.

20. Zhu Y., Ye X., Zhu B., Pei X., Wei L., Wu J., Zhao W. (2014). Comparisons between the 2012 new CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations and other four approved equations. PlosOne, 9 (1): e84688. doi: 10.1371/journal.pone.0084688